Goldman Sachs Reinstates Neutral on Altimmune, Announces $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has reinstated coverage on Altimmune (NASDAQ:ALT) with a Neutral rating and set a price target of $13.

January 24, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has reinstated Altimmune with a Neutral rating and a price target of $13, which could influence the stock's performance.
The reinstatement of coverage by Goldman Sachs with a Neutral rating and a specific price target provides investors with a professional analysis of Altimmune's stock value. While a Neutral rating does not suggest a strong buy or sell signal, the setting of a price target can serve as a benchmark for investors, potentially stabilizing the stock price around the target level if the market aligns with the analyst's view. However, the impact may be moderate as the rating is neutral, indicating that the analyst does not see significant upside or downside in the near term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100